BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 21328373)

  • 1. Association of intrahepatic cccDNA reduction with the improvement of liver histology in chronic hepatitis B patients receiving oral antiviral agents.
    Cheng PN; Liu WC; Tsai HW; Wu IC; Chang TT; Young KC
    J Med Virol; 2011 Apr; 83(4):602-7. PubMed ID: 21328373
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Covalently closed-circular hepatitis B virus DNA reduction with entecavir or lamivudine.
    Bowden S; Locarnini S; Chang TT; Chao YC; Han KH; Gish RG; de Man RA; Yu M; Llamoso C; Tang H
    World J Gastroenterol; 2015 Apr; 21(15):4644-51. PubMed ID: 25914474
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Entecavir 1.0mg monotherapy or entecavir plus adefovir dipivoxil for patients with lamivudine-resistant chronic hepatitis B had suboptimal response to lamivudine plus adefovir dipivoxil].
    Xing J; Han T; Liu L; Li Y; Li J; Li Y; Xiao SX
    Zhonghua Gan Zang Bing Za Zhi; 2011 Nov; 19(11):828-32. PubMed ID: 22433304
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rescue therapy for lamivudine-resistant chronic hepatitis B: comparison between entecavir 1.0 mg monotherapy, adefovir monotherapy and adefovir add-on lamivudine combination therapy.
    Kim HJ; Park JH; Park DI; Cho YK; Sohn CI; Jeon WK; Kim BI
    J Gastroenterol Hepatol; 2010 Aug; 25(8):1374-80. PubMed ID: 20659226
    [TBL] [Abstract][Full Text] [Related]  

  • 5. One-year entecavir or lamivudine therapy results in reduction of hepatitis B virus intrahepatic covalently closed circular DNA levels.
    Wong DK; Yuen MF; Ngai VW; Fung J; Lai CL
    Antivir Ther; 2006; 11(7):909-16. PubMed ID: 17302253
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictive value of intrahepatic hepatitis B virus covalently closed circular DNA and total DNA in patients with acute hepatitis B and patients with chronic hepatitis B receiving anti‑viral treatment.
    Ruan P; Zhou B; Dai X; Sun Z; Guo X; Huang J; Gong Z
    Mol Med Rep; 2014 Apr; 9(4):1135-41. PubMed ID: 24566465
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lamivudine plus adefovir or entecavir for patients with chronic hepatitis B resistant to lamivudine and adefovir.
    Heo NY; Lim YS; Lee HC; Chung YH; Lee YS; Suh DJ
    J Hepatol; 2010 Sep; 53(3):449-54. PubMed ID: 20646776
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adefovir-based combination therapy with entecavir or lamivudine for patients with entecavir-refractory chronic hepatitis B.
    Kim SS; Cheong JY; Lee D; Lee MH; Hong SP; Kim SO; Cho SW
    J Med Virol; 2012 Jan; 84(1):18-25. PubMed ID: 22028068
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of entecavir on hepatitis B virus covalently closed circular DNA in hepatitis B e antigen-positive patients with hepatitis B.
    Shi M; Sun WL; Hua YY; Han B; Shi L
    PLoS One; 2015; 10(2):e0117741. PubMed ID: 25647607
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quantitative analysis of HBV cccDNA from clinical specimens: correlation with clinical and virological response during antiviral therapy.
    Bourne EJ; Dienstag JL; Lopez VA; Sander TJ; Longlet JM; Hall JG; Kwiatkowski RW; Wright T; Lai CL; Condreay LD
    J Viral Hepat; 2007 Jan; 14(1):55-63. PubMed ID: 17212645
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B.
    Wursthorn K; Lutgehetmann M; Dandri M; Volz T; Buggisch P; Zollner B; Longerich T; Schirmacher P; Metzler F; Zankel M; Fischer C; Currie G; Brosgart C; Petersen J
    Hepatology; 2006 Sep; 44(3):675-84. PubMed ID: 16941693
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.
    Marcellin P; Heathcote EJ; Buti M; Gane E; de Man RA; Krastev Z; Germanidis G; Lee SS; Flisiak R; Kaita K; Manns M; Kotzev I; Tchernev K; Buggisch P; Weilert F; Kurdas OO; Shiffman ML; Trinh H; Washington MK; Sorbel J; Anderson J; Snow-Lampart A; Mondou E; Quinn J; Rousseau F
    N Engl J Med; 2008 Dec; 359(23):2442-55. PubMed ID: 19052126
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationship between serum hepatitis B virus DNA and surface antigen with covalently closed circular DNA in HBeAg-negative patients.
    Lin LY; Wong VW; Zhou HJ; Chan HY; Gui HL; Guo SM; Wang H; Huang L; Bao SS; Xie Q; Chan HL
    J Med Virol; 2010 Sep; 82(9):1494-500. PubMed ID: 20648602
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiviral efficacy of combination therapy with entecavir and adefovir for entecavir/lamivudine-resistant hepatitis B virus with or without adefovir resistance.
    Yang HJ; Lee JH; Kim YJ; Yoon JH; Lee HS
    J Med Virol; 2012 Mar; 84(3):424-30. PubMed ID: 22246827
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evolution of hepatitis B virus mutation during entecavir rescue therapy in patients with antiviral resistance to lamivudine and adefovir.
    Choe WH; Hong SP; Kim BK; Ko SY; Jung YK; Kim JH; Yeon JE; Byun KS; Kim KH; Ji SI; Kim SO; Lee CH; Kwon SY
    Antivir Ther; 2009; 14(7):985-93. PubMed ID: 19918102
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of entecavir in patients with chronic hepatitis B resistant to both lamivudine and adefovir or to lamivudine alone.
    Shim JH; Suh DJ; Kim KM; Lim YS; Lee HC; Chung YH; Lee YS
    Hepatology; 2009 Oct; 50(4):1064-71. PubMed ID: 19637288
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sequential combination therapy leads to biochemical and histological improvement despite low ongoing intrahepatic hepatitis B virus replication.
    Lutgehetmann M; Volzt T; Quaas A; Zankel M; Fischer C; Dandri M; Petersen J
    Antivir Ther; 2008; 13(1):57-66. PubMed ID: 18389899
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy.
    Werle-Lapostolle B; Bowden S; Locarnini S; Wursthorn K; Petersen J; Lau G; Trepo C; Marcellin P; Goodman Z; Delaney WE; Xiong S; Brosgart CL; Chen SS; Gibbs CS; Zoulim F
    Gastroenterology; 2004 Jun; 126(7):1750-8. PubMed ID: 15188170
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multidrug-resistant hepatitis B virus resulting from sequential monotherapy with lamivudine, adefovir, and entecavir: clonal evolution during lamivudine plus adefovir therapy.
    Kim SS; Cho SW; Kim SO; Hong SP; Cheong JY
    J Med Virol; 2013 Jan; 85(1):55-64. PubMed ID: 23096938
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intrahepatic levels and replicative activity of covalently closed circular hepatitis B virus DNA in chronically infected patients.
    Laras A; Koskinas J; Dimou E; Kostamena A; Hadziyannis SJ
    Hepatology; 2006 Sep; 44(3):694-702. PubMed ID: 16941694
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.